Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy
Objectives To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). Methods Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. Results Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p < 0.001). HLA-DR was perifascicular in ASM, a pattern not observed in DM. In addition, C5b-9 deposition was observed on sarcolemma of non-necrotic perifascicular fibers in ASM, while, in DM, C5b-9was mainly detected in endomysial capillaries. CD8 cells were more abundant in ASM than in DM (p < 0.05), and electively located in perimysium or in perifascular endomysium. HLA-DR expression correlated positively with the CD8+ cells infiltrates. Strictly similar observations were made in the confirmatory study. Conclusion ASM is characterized by strong myofiber MHC-II/HLA-DR expression with a unique perifascicular pattern, not described so far. HLA-DR detection must be included for routine myopathological diagnosis of inflammatory/dysimmune myopathies. HLA-DR expression in ASM may indicate a specific immune mechanism, possibly involving IFNγ..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Acta Neuropathologica Communications - 2(2014), 1 vom: 23. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aouizerate, Jessie [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Anti-synthetase |
|---|
| Anmerkungen: |
© Aouizerate et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( |
|---|
| doi: |
10.1186/s40478-014-0154-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR036508268 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR036508268 | ||
| 003 | DE-627 | ||
| 005 | 20230519195015.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40478-014-0154-2 |2 doi | |
| 035 | |a (DE-627)SPR036508268 | ||
| 035 | |a (SPR)s40478-014-0154-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aouizerate, Jessie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Aouizerate et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( | ||
| 520 | |a Objectives To assess the value of major histocompatibility complex (MHC) class II antigen (HLA-DR) expression to distinguish anti-synthetase myopathy (ASM) from dermatomyositis (DM). Methods Muscle biopsies from patients with ASM (n = 33), DM without anti-synthetase antibodies (ASAb) (n = 17), and normal muscle biopsy (n = 10) were first reviewed. ASAb included anti-Jo1 (26/33), anti-PL12 (4/33), anti-PL7 (2/33), and anti-EJ (1/33). Immunohistochemistry was performed for MHC-I/HLA-ABC, MHC-II/HLA-DR, membrane attack complex (C5b-9), neural cell adhesion molecule (NCAM)/CD56 expression, and inflammatory cell subsets. Twenty-four ASM and 12 DM patients from another center were added for HLA-DR evaluation. Results Ubiquitous myofiber HLA-ABC expression was equally observed in ASM and DM (93.9% vs 100%, NS). In contrast, myofiber HLA-DR expression was found in 27/33 (81.8%) ASM (anti-Jo1: 23/26, 88.5%; others: 5/7, 71.4%) vs 4/17 (23.5%) DM patients (p < 0.001). HLA-DR was perifascicular in ASM, a pattern not observed in DM. In addition, C5b-9 deposition was observed on sarcolemma of non-necrotic perifascicular fibers in ASM, while, in DM, C5b-9was mainly detected in endomysial capillaries. CD8 cells were more abundant in ASM than in DM (p < 0.05), and electively located in perimysium or in perifascular endomysium. HLA-DR expression correlated positively with the CD8+ cells infiltrates. Strictly similar observations were made in the confirmatory study. Conclusion ASM is characterized by strong myofiber MHC-II/HLA-DR expression with a unique perifascicular pattern, not described so far. HLA-DR detection must be included for routine myopathological diagnosis of inflammatory/dysimmune myopathies. HLA-DR expression in ASM may indicate a specific immune mechanism, possibly involving IFNγ. | ||
| 650 | 4 | |a HLA-DR |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Inflammatory myopathy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dermatomyositis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anti-synthetase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Complement |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a De Antonio, Marie |4 aut | |
| 700 | 1 | |a Bassez, Guillaume |4 aut | |
| 700 | 1 | |a Gherardi, Romain K |4 aut | |
| 700 | 1 | |a Berenbaum, Francis |4 aut | |
| 700 | 1 | |a Guillevin, Loïc |4 aut | |
| 700 | 1 | |a Berezne, Alice |4 aut | |
| 700 | 1 | |a Valeyre, Dominique |4 aut | |
| 700 | 1 | |a Maisonobe, Thierry |4 aut | |
| 700 | 1 | |a Dubourg, Odile |4 aut | |
| 700 | 1 | |a Cosnes, Anne |4 aut | |
| 700 | 1 | |a Benveniste, Olivier |4 aut | |
| 700 | 1 | |a Authier, François Jérôme |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta Neuropathologica Communications |d London : Biomed Central, 2013 |g 2(2014), 1 vom: 23. Okt. |w (DE-627)SPR036506710 |w (DE-600)2715589-4 |x 2051-5960 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2014 |g number:1 |g day:23 |g month:10 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40478-014-0154-2 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2014 |e 1 |b 23 |c 10 | ||